Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$9.3 - $16.6 $70,680 - $126,160
-7,600 Reduced 12.44%
53,500 $615,000
Q2 2023

Aug 14, 2023

BUY
$7.66 - $16.46 $159,328 - $342,368
20,800 Added 51.61%
61,100 $1.01 Million
Q1 2023

May 15, 2023

BUY
$1.46 - $12.54 $41,172 - $353,628
28,200 Added 233.06%
40,300 $359,000
Q4 2022

Feb 14, 2023

BUY
$0.41 - $4.54 $4,961 - $54,934
12,100 New
12,100 $27,000

Others Institutions Holding AMAM

About Ambrx Biopharma Inc.


  • Ticker AMAM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,618,400
  • Market Cap $1.08B
  • Description
  • Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...
More about AMAM
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.